title: CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
abstract: Signaling lymphocytic activation molecule (SLAM) family receptors have been implicated in normal immunity, immunodeficiencies and autoimmunity. CS1 (also known as CRACC, CD319 and SLAMF7) is a member of the SLAM family expressed on several normal hematopoietic cell types. It is also highly and nearly universally expressed on multiple myeloma (MM) cells. This review focuses on the biology of CS1, both in normal hematopoietic cells and in MM cells. It also discusses the preclinical and clinical data on the use of a humanized anti-CS1 monoclonal antibody, elotuzumab, for the treatment of MM. Based on current knowledge, CS1 is a compelling new target for the treatment of MM.
authors.affiliation: Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec, Canada H2W 1R7; Department of Medicine, McGill University, Montréal, Québec, Canada H3G 1Y6; Department of Medicine, University of Montréal, Montréal, Québec, Canada H3T 1J4. Electronic address: Andre.Veillette@ircm.qc.ca.
authors.forename: André
authors.initials: A
authors.lastname: Veillette
authors.forename: Huaijian
authors.initials: H
authors.lastname: Guo
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D000071176:Signaling Lymphocytic Activation Molecule Family
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011971:Receptors, Immunologic; C448987:SLAMF7 protein, human; D000071176:Signaling Lymphocytic Activation Molecule Family
keywords: CRACC; CS1; EAT-2; Elotuzumab; Multiple myeloma; SAP; SLAM